When purchasing hemp derived topical products, the adage of “Let the buyer beware” could have new meaning. Are you really getting what you’re paying for? Can you trust the label? A recent study suggests you can’t. A new study in JAMA Network Open (July 2022) examines the accuracy of cannabinoid[Read More…]
Tag: CBD
CBD: Shown ineffective in treatment of drug-resistant Epilepsy
Cannabidiol (CBD) has shown to be effective in treating specific pediatric seizure disorders. Researchers explored if CBD would be effective in treating drug-resistant epilepsy in reducing seizures in adults, it was not. In a double-blind, placebo-controlled study conducted in Australia and New Zealand, 188 people with drug-resistant epilepsy were dosed[Read More…]
CDC Issues Health Warning: Delta-8 THC
Cannabis-based products with Delta-8 THC are gaining popularity in many markets as consumers believe that Delta-8 is a safer alternative when compared to its more potent cousin, Delta-9 THC. It’s important to remember that “safer” does not mean devoid of risks. A recent “Health Advisory” from the Centers for Disease[Read More…]
THC Levels in Med & Rec States: Pain Management
Pain is the leading reason cited why people use medical marijuana in the United States. Marijuana with low potency levels of tetrahydrocannabinol (THC), i.e. under 5-10%, has shown some efficacy in pain management. However, that’s in stark contrast to the advertised high THC potency levels of marijuana products sold both[Read More…]
Cannabis Policy: Recommendations from the United States Senate Caucus
The United States Senate Caucus recently issued a report titled, “Cannabis Policy, Public Health and Safety, Issues and Recommendations”. The report focused on five (5) key areas: (1) Barriers to Researching Cannabis, (2) Impacts of Increased Cannabis Potency, (3) Cannabis Use on the Developing Brain, (4) Unregulated Products and (5) Cannabis[Read More…]